Back to search

Boston University

The cost efficiency of semaglutide in patients with obesity

Abstract

dc:description.abstract

The number of Americans who are diagnosed with obesity and type 2 diabetes mellitus has been on a steady incline for at least the past 20 years. An increase in the number of patients struggling with these diseases comes with what seems like a correlating increase in the costs of healthcare. Significant innovations have been improving the quality of life and treating obesity and diabetes since the 1960s. However, with the increases in costs of care, it is important to understand the cost efficacy of newer medications periodically to gain a comprehensive understanding of the cost efficacy of these medications in improving the quality of life and health of these patients. Therefore, this paper will focus on the cost efficacy of Semaglutide, a new drug that functions as a glucagon-like peptide-1 (GLP-1) agonist. Other drugs and procedures on the market, such as Liraglutide, Contrave, Orlistat, phentermine-topiramate, and gastric bypass surgery, will be used as a comparison for Semaglutide. Based on a year's supply of the drug and the percentage of weight lost, the cost to lose weight was found. Then, based on the percent weight lost, the projected savings in medical care expenditure were calculated. This results in a ratio that compares the benefits to the cost of the medication. As a result, Semaglutide was effective in reducing weight; however, the price of the drug makes it less cost-efficient than other options on the market. However, it still has its place as it is still more cost-efficient than other medications, and it also has a different mechanism of action, which helps prove useful for certain types of patients.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Luo, Andrew
Advisors dc:contributor.advisor
  • Offner, Gwynneth
  • Gong, Haiyan

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/51820

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Luo, Andrew. The cost efficiency of semaglutide in patients with obesity. masters thesis, Boston University, 2024. https://hdl.handle.net/2144/51820